IDH2 and glioblastoma: The relative insensitivity of mIDH1 glioblastoma carry significant implication in terms of the glioblastoma treatment paradigm, particularly in the context of the ever-expanding number of potential tumoricidal and immuno-therapies specifically targeting IDH mutations [34–36].